| ICD Code | Description |
|---------|-------------|
| 403.00  | Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified |
| 403.01  | Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end-stage renal disease |
| 403.10  | Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified |
| 403.11  | Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end-stage renal disease |
| 403.90  | Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified |
| 403.91  | Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end-stage renal disease |
| 404.00  | Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified |
| 404.01  | Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified |
| 404.02  | Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end-stage renal disease |
| 404.03  | Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end-stage renal disease |
| 404.10  | Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified |
| 404.11  | Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified |
| 404.12  | Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end-stage renal disease |
| 404.13  | Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end-stage renal disease |
| 404.90  | Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified |
| 404.91  | Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified |
| 404.92  | Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end-stage renal disease |
| 404.93  | Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end-stage renal disease |
| 580.0   | Acute glomerulonephritis with lesion of proliferative glomerulonephritis |
| 580.4   | Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis |
| 580.81  | Acute glomerulonephritis with other specified pathologic lesion in kidney in disease classified elsewhere |
| 580.89  | Other acute glomerulonephritis with other specified pathologic lesion in kidney |
| Code   | Description                                                                 |
|--------|-----------------------------------------------------------------------------|
| 580.9  | Acute glomerulonephritis with unspecified pathologic lesion in kidney       |
| 581.0  | Nephrotic syndrome with lesion of proliferative glomerulonephritis          |
| 581.1  | Nephrotic syndrome with lesion of membranous glomerulonephritis             |
| 581.2  | Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis  |
| 581.3  | Nephrotic syndrome with lesion of minimal change glomerulonephritis         |
| 581.81 | Nephrotic syndrome with other specified pathologic lesion in kidney in diseases classified elsewhere |
| 581.89 | Other nephrotic syndrome with specified pathologic lesion in kidney         |
| 581.9  | Nephrotic syndrome with unspecified pathologic lesion in kidney             |
| 582.0  | Chronic glomerulonephritis with lesion of proliferative glomerulonephritis  |
| 582.1  | Chronic glomerulonephritis with lesion of membranous glomerulonephritis     |
| 582.2  | Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis |
| 582.4  | Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis |
| 582.81 | Chronic glomerulonephritis with other specified pathologic lesion in kidney in diseases classified elsewhere |
| 582.89 | Other chronic glomerulonephritis with specified pathologic lesion in kidney |
| 582.9  | Chronic glomerulonephritis with unspecified pathologic lesion in kidney     |
| 583.0  | Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis |
| 583.1  | Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis |
| 583.2  | Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis |
| 583.4  | Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis |
| 583.6  | Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis |
| 583.7  | Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis |
| 583.81 | Nephritis and nephropathy, not specified as acute or chronic, with other specified pathologic lesion in kidney, in diseases classified elsewhere |
| 583.89 | Other nephritis and nephropathy, not specified as acute or chronic, with specified pathologic lesion in kidney |
| 583.9  | Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathologic lesion in kidney |
| 584.5  | Acute kidney failure with lesion of tubular necrosis                        |
| 584.6  | Acute kidney failure with lesion of renal cortical necrosis                 |
| 584.7  | Acute kidney failure with lesion of medullary (papillary) necrosis          |
| 584.8  | Acute kidney failure with other specified pathologic lesion in kidney       |
| 584.9  | Acute kidney failure, unspecified                                           |
| 585.1  | Chronic kidney disease, Stage I                                             |
| 585.2  | Chronic kidney disease, stage II (mild)                                     |
| 585.3  | Chronic kidney disease, stage III (moderate)                                |
| 585.4  | Chronic kidney disease, stage IV (severe)                                   |
| 585.6  | End-stage renal disease                                                     |
| Code  | Description                                           |
|-------|-------------------------------------------------------|
| 585.9 | Chronic kidney disease, unspecified                  |
| 586   | Unspecified renal failure                            |
| 588.0 | Renal osteodystrophy                                 |
| 588.1 | Nephrogenic diabetes insipidus                       |
| 588.81| Secondary hyperparathyroidism (of renal origin)       |
| 588.89| Other specified disorders resulting from impaired renal function |
| 588.9 | Unspecified disorder resulting from impaired renal function |
| 593.9 | Unspecified disorder of kidney and ureter            |
Online Resource 2. Flow of patients by FN risk category. FN, febrile neutropenia; NHL, non-Hodgkin's lymphoma. *Projectable means that the physician administering the product and/or the pharmacy where the product was dispensed met all criteria for projections (i.e., had identifiable values for each step in the extrapolation). Patients that could not be classified as high, intermediate, low, or none risk per NCCN guidelines were removed from the study.
**Online Resource 3. The Five Most Frequent Regimens Administered for Metastatic and Nonmetastatic Disease**

| Regimen                                                                 | Tumor Type      | Schedule | Chemotherapy Cycles, n |
|------------------------------------------------------------------------|-----------------|----------|------------------------|
| **Nonmetastatic**                                                       |                 |          |                        |
| High risk                                                               |                 |          |                        |
| Cyclophosphamide and doxorubicin, followed by paclitaxel                | Breast          | Q2W      | 63,047                 |
| Cyclophosphamide, doxorubicin                                          | Breast          | Q2W      | 21,334                 |
| Cyclophosphamide, docetaxel, doxorubicin                               | Breast          | Q3W      | 15,407                 |
| Cisplatin, docetaxel, fluorouracil                                     | Head and neck   | Other    | 2,455                  |
| Cyclophosphamide, docetaxel, doxorubicin                               | Breast          | Other    | 2,082                  |
| **Intermediate risk**                                                  |                 |          |                        |
| Fluorouracil, oxaliplatin                                              | Colorectal      | Q2W      | 152,318                |
| Cyclophosphamide, doxorubicin followed by paclitaxel                    | Breast          | QW       | 130,638                |
| Cyclophosphamide, docetaxel                                            | Breast          | Q3W      | 96,851                 |
| Carboplatin, docetaxel, trastuzumab                                    | Breast          | Q3W      | 95,401                 |
| Carboplatin, docetaxel, trastuzumab                                    | Breast          | Other    | 86,765                 |
| **Low risk**                                                           |                 |          |                        |
| Paclitaxel, trastuzumab                                               | Breast          | Other    | 79,803                 |
| Paclitaxel, trastuzumab                                               | Breast          | QW       | 41,001                 |
| Cisplatin                                                             | Gynecologic     | QW       | 16,774                 |
| Paclitaxel, trastuzumab                                               | Breast          | Q3W      | 9,204                  |
| Treatment                                   | Tumor Type   | Schedule | All | Count |
|--------------------------------------------|--------------|----------|-----|-------|
| Doxorubicin liposomal                      | Gynecologic  | Q4W+     | 2,486 |       |
| Metastatic                                 |              |          |     |       |
| High risk                                  |              |          |     |       |
| Cyclophosphamide, doxorubicin, rituximab,  | Non-Hodgkin’s|          | All | 112,032|
| vincristine                                | lymphoma     |          |     |       |
| Topotecan                                  | Lung         | All      | 25,205 |       |
| Topotecan                                  | Ovarian      | All      | 19,385 |       |
| Paclitaxel                                 | Ovarian      | All      | 17,860 |       |
| Cyclophosphamide, doxorubicin followed by  | Breast       | Q2W      | 16,693 |       |
| paclitaxel                                 |              |          |     |       |
| Intermediate risk                          |              |          |     |       |
| Bevacizumab, fluorouracil, oxaliplatin     | Colorectal   | All      | 131,752 |       |
| Carboplatin, paclitaxel                    | Lung         | All      | 79,821 |       |
| Fluorouracil, oxaliplatin                  | Colorectal   | All      | 62,455 |       |
| Cyclophosphamide, doxorubicin followed by  | Breast       | All      | 53,950 |       |
| paclitaxel                                 |              |          |     |       |
| Carboplatin, paclitaxel protein-bound      | Lung         | All      | 52,973 |       |
| Low risk                                   |              |          |     |       |
| Bevacizumab, irinotecan                    | Colorectal   | All      | 136,201 |       |
| Trastuzumab                                | Breast       | All      | 119,883 |       |
| Paclitaxel protein-bound particles         | Breast       | All      | 117,765 |       |
| Rituximab                                  | Non-Hodgkin’s| All      | 102,898 |       |
| Carboplatin, pemetrexed | Lung | All | 93,548 |
|------------------------|------|-----|--------|
| QW, every week; Q2W, every 2 weeks; Q3W, every 3 weeks; Q4W+, every 4 weeks or more. |